HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY

被引：0
|
作者：
Collin, S. [1 ]
Tse, J. [2 ]
Shaikh, N. F. [3 ]
Near, A. [2 ]
Hamilton, E. [4 ]
Brufsky, A. [5 ]
Gradishar, W. [6 ]
Mehta, S. [7 ]
Long, G. H. [1 ]
Toms, N. [1 ]
机构：
[1] AstraZeneca Pharmaceut Ltd, Cambridge, England
[2] IQVIA, Durham, NC USA
[3] IQVIA, Morgantown, WV USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[7] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE417
引用
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [31] VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/HER2-METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY
    Richardson, D.
    Zhan, L.
    Reynolds, M.
    Odom, D.
    McRoy, L.
    Mitra, D.
    Zelnak, A.
    Jones, C.
    VALUE IN HEALTH, 2019, 22 : S527 - S527
  • [32] Results of a retrospective study on the efficacy and safety of alpelisib in patients with HR+/HER2-metastatic breast cancer in real-world clinical practice
    Sultanbaev, Alexander Valerievich
    Kolyadina, Irina Vladimirovna
    Menshikov, Konstantin
    Musin, Shamil
    Sultanbaeva, Nadezda
    Lipatov, Danila
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
  • [34] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [35] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Current Treatment Patterns Among Postmenopausal Women with HR+/HER2-Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
    Goldschmidt, Deborah
    Dalal, Anand A.
    Romdhani, Hela
    Kelkar, Sneha
    Guerin, Annie
    Gauthier, Genevieve
    Wu, Eric Q.
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (04) : 482 - 493
  • [37] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [38] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [39] Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2-metastatic breast cancer: A retrospective chart review study in the US
    Li, N.
    Ohashi, E.
    Koo, V.
    Xie, J.
    Hao, Y.
    Tang, D. H.
    CANCER RESEARCH, 2017, 77
  • [40] Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis
    Waks, A. G.
    Gharaibeh, M.
    Sjekloca, N.
    Poluparthi, N.
    Shah, A.
    Bergamaco, E.
    MacCannell, T.
    Leung, G.
    Ntalla, I.
    Oko-osi, H.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S653 - S653
12345